Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +14

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2018 · 1.7K citations · Full text

Medicine, Internal Medicine, Oncology +5

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema et al. · New England Journal of Medicine · 2018 · 952 citations · Full text

Medicine, Immunology, Oncology +10

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · New England Journal of Medicine · 2018 · 909 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo et al. · New England Journal of Medicine · 2019 · 852 citations

Pharmacy, Pharmacology, Pharmacotherapy +14